13D Filing: OrbiMed Advisors and Loxo Oncology Inc. (LOXO)

Page 3 of 12

Page 3 of 12 – SEC Filing

SCHEDULE 13D
CUSIP No.  548862101
Page 3 of 13 Pages
1
NAME OF REPORTING PERSONS
OrbiMed Capital GP V LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)
(b)
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
N/A
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
1,458,000
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
1,458,000
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,458,000
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.87%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
_______________________
*This percentage is calculated based upon 29,937,504 shares of the Issuer’s Common Stock (defined below) outstanding as of October 31, 2017, as reported in the Issuer’s Form 10-Q filed with the Securities Exchange Commission (the “SEC”) on November 2, 2017.

Follow Loxo Oncology Inc. (NASDAQ:LOXO)

Page 3 of 12